05 July 2018
Bain Capital Private Equity has agreed to acquire DSM Sinochem Pharmaceuticals (DSP), the global leader in sustainable antibiotics, next-generation statins and anti-fungals. DSP is a 50/50 joint venture of Heerlen-based DSM and Sinochem of Beijing. DSM said it was paid about €250m for its stake in the group. In 2017, DSP generated sales of approximately €440m. It has manufacturing sites and sales offices in China, India, the Netherlands, Spain, the US and Mexico, with approximately 2,000 employees. ‘DSM and Sinochem have been great supporters of our vision to be the global leader in generic pharmaceuticals,’ said Karl Rotthier, who heads DSP. ‘Bain Capital is now the ideal partner to drive DSP into its next stage of global development, given its deep healthcare expertise and operational skills across its worldwide team,’ he said.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
29 July 2021
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.